Jodi K Maranchie MD
Minimally Invasive Surgery, Surgical Oncology, Trauma & Reconstructive Surgery
Assistant Professor, Urology, University of Pittsburgh School of Medicine
Join to View Full Profile
5200 Centre AveSte 209Pittsburgh, PA 15232
Phone+1 412-605-3019
Fax+1 412-605-3030
Dr. Maranchie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Minimally Invasive Urologic Surgery, 1999 - 2002
Mass General Brigham/Brigham and Women's Hospital/Harvard Medical SchoolResidency, Urology, 1995 - 1999- Mass General Brigham/Brigham and Women's HospitalResidency, Surgery, 1993 - 1995
Northwestern University The Feinberg School of MedicineClass of 1993
Certifications & Licensure
PA State Medical License 2006 - 2026
MA State Medical License 1994 - 2007
MD State Medical License 1999 - 2001
American Board of Urology Urology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma Start of enrollment: 2010 Oct 01
- Virtual Histology of the Bladder Wall for Bladder Cancer Staging Start of enrollment: 2021 Jan 06
Publications & Presentations
PubMed
- 1 citationsImpact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.Stephanie A Berg, Salvatore La Rosa, Tian Zhang, Phillip M Pierorazio, Laurence Albiges
Urologic Oncology. 2025-03-01 - Corrigendum.Henry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, Jay Chhablani, Ane Bundsbæk Bøndergaard Iversen
Ophthalmology. 2025-03-01 - 2 citationsOral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.Henry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, Jay Chhablani, Ane Bundsbæk Bøndergaard Iversen
Ophthalmology. 2024-11-01
Press Mentions
Mounting Drug Shortages Delay Treatments for Patients with Bladder CancerNovember 27th, 2019
AUA 2019: How Are We Improving Outcomes of Locally Advanced RCC?May 5th, 2019
The Power of Artificial Intelligence in Urology - Jodi MaranchieNovember 18th, 2023
Grant Support
- Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL RecruitmentUNIVERSITY OF PITTSBURGH AT PITTSBURGH2021–2026
- Nox4 Induction of HIF-alpha in Renal TumorigenesisAmerican Cancer Society2009–2013
- Nox4 Targeted Therapy for Kidney CancerThe Pittsburgh Foundation2007–2009
- Impact Of Renox On Hif-Alpha In Renal CancerNational Institute Of Diabetes And Digestive And Kidney Diseases2007
- Imapct Of Renox On Hif-Alpha In Renal CancerNational Institute Of Diabetes And Digestive And Kidney Diseases2006
- Imapct Of Renox On Hif-Alpha In Renal CancerNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2006
- Impact Of Renox On Hif-Alpha In Renal CancerNational Institute Of Diabetes And Digestive And Kidney Diseases2003
Professional Memberships
- Member
- Society for Basic Urologic ResearchMember
- The Society of Urologic OncologyMember
- Society of Women in UrologyMember
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
